** Shares of gene therapy maker bluebird bio rise as much as 2.3% to 49 cents premarket; last up 1%
** Co says it will cut approximately 25% of its workforce as part of its restructuring to optimize cash flow break-even in H2 2025
** Restructuring also to reduce operating cash expenses by 20% - co
** BLUE says it will incur aggregate charged worth $3.7 mln as a result of restructuring, to be paid out through fiscal year ending Dec. 31
** As of June 30, 2024, co had 375 full-time employees
** As of last close, stock down 64.6% YTD
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。